ENGLEWOOD, Colo., Nov. 10, 2021 /PRNewswire/ -- Zynex, Inc.
(NASDAQ: ZYXI), an innovative medical technology company
specializing in the manufacture and sale of non-invasive medical
devices for pain management, stroke rehabilitation, cardiac
monitoring and neurological diagnostics, today announced it has
declared a one-time special cash dividend of $0.10 per share and a stock dividend of 10% per
share. Both dividends are on its Common Stock. The dividends are
payable to all common stockholders of record as of the close of
business on January 6, 2022, payable
on or about January 21, 2022. Based
on the current number of shares outstanding the cash dividend is
expected to result in an aggregate distribution of approximately
$3.5 million. The stock dividend will
result in an issuance of approximately 3.5 million additional
shares of common stock.
Thomas Sandgaard, CEO, Chairman
and Founder said: "With our continued strong financial performance,
it is appropriate to reward our shareholders for their support.
Returning capital to shareholders reflects our strong financial
position and confidence in our future. Following this dividend, our
cash balance remains strong and provides us the flexibility to
expand our business both through acquisitions and organic
growth."
About Zynex, Inc.
Zynex, founded in
1996, markets and sells its own design of electrotherapy medical
devices used for pain management and rehabilitation; and the
company's proprietary NeuroMove device designed to help recovery of
stroke and spinal cord injury patients. Zynex also has a fluid
monitoring system for use in hospitals and surgery centers. For
additional information, please visit: www.zynex.com.
Safe Harbor Statement
This release contains forward-looking statements within the
meaning of the safe harbor provisions of the U.S. Private
Securities Litigation Reform Act of 1995.
Forward-looking statements are neither historical facts nor
assurances of future performance. Instead, they are based only on
our current beliefs, expectations and assumptions regarding the
future of our business, future plans and strategies, projections,
anticipated events and trends, the economy and other future
conditions. Because forward-looking statements relate to
the future, they are subject to inherent uncertainties, risks and
changes in circumstances that are difficult to predict and many of
which are outside of our control. Our actual results and financial
condition may differ materially from those indicated in the
forward-looking statements. Therefore you should not rely on any of
these forward looking statements. The Company makes no
express or implied representation or warranty as to the
completeness of forward-looking statements or, in the case of
projections, as to their attainability or the accuracy and
completeness of the assumptions from which they are derived.
Factors that could cause actual results to materially differ from
forward-looking statements include, but are not limited to, the
need to obtain CE marking of new products, the acceptance of new
products as well as existing products by doctors and hospitals,
larger competitors with greater financial resources, the need to
keep pace with technological changes, our dependence on the
reimbursement for our products from health insurance companies, our
dependence on third party manufacturers to produce our products on
time and to our specifications, implementation of our sales
strategy including a strong direct sales force, the impact of
COVID-19 on the global economy and other risks described in our
filings with the Securities and Exchange Commission including but
not limited to, our Annual Report on Form 10-K for the year
ended December 31, 2020 as well as our quarterly reports
on Form 10-Q and current reports on Form 8-K.
Any forward-looking statement made by us in this release is
based only on information currently available to us and speaks only
as of the date on which it is made. We undertake no obligation to
publicly update any forward-looking statement, whether written or
oral, that may be made from time to time, whether as a result of
new information, future developments or otherwise.
Contact: Zynex, Inc. (800) 495-6670
Investor Relations Contact:
Amato And Partners,
LLC
Investor Relations Counsel
admin@amatoandpartners.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/zynex-declares-special-cash-dividend-of-0-10-per-share-and-10-stock-dividend-301421138.html
SOURCE Zynex